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Background: Syncope carries a poor prognosis among patients with dilated cardiomyopathy
(DCM).
Objectives: To assess the prevalence, describe the underlying mechanisms and to identify
risk factors for syncope in patients with DCM.
Methods: One thousand six hundred and ten medical ﬁles of 897 patients with a diagnosis of
DCM were reviewed. Patients with syncope were identiﬁed and their clinical and paraclinical
proﬁles were compared to an equal number of age- and sex-matched patients with DCM
without syncope.
Results: Thirty patients (27 males) with an average age of 62.5 years were identiﬁed,
corresponding to a prevalence of syncope of 3.3%. A cardiac origin of syncope was identiﬁed
in 56% of patients (n = 17): ventricular arrhythmias in 33% (n = 10), and conduction disorders
in 23% (n = 7). Other mechanisms of syncope were neurally mediated in 7% (n = 2) and
orthostatic hypotension in 7% (n = 2). In 30% of cases (n = 9), the etiology was unidentiﬁed.
There were no signiﬁcant differences regarding the etiology of DCM, ejection fraction
(35.3% vs 35.3%, p = 1.0), NYHA class (mild or advanced, p = 0.79) and associated conditions
(hypertension, p = 0.36; diabetes, p = 0.75; atrial ﬁbrillation, p = 0.43; and dyslipidemia,
p = 0.33) between the two groups. However, among patients with syncope, patients with
a noncardiac cause were more likely to have hypertension (61.53% vs 23.52%, p = 0.08) and
diabetes (46.15% vs 5.88%, p = 0.03).
Conclusion: In patients with DCM, syncope is a relatively rare ﬁnding. Cardiac causes
(arrhythmias and conduction disorders) are responsible for the majority of cases. Risk
factors for syncope in these patients remain to be determined.
# 2015 Cardiological Society of India. Published by Elsevier, a division of Reed Elsevier
India, Pvt. Ltd. All rights reserved.
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The occurrence of syncope in patients with congestive heart
failure (HF) and left ventricular (LV) dysfunction is related to an* Corresponding author.
E-mail address: lmure_san@yahoo.com (M. Lucian).
http://dx.doi.org/10.1016/j.ihj.2015.09.025
0019-4832/# 2015 Cardiological Society of India. Published by Elsevierincreased risk of overall mortality and sudden cardiac death
(SCD).1,2 The one-year risk of SCD can be as high as 45% in
subjects with advanced HF and syncope, compared to a
signiﬁcantly lower SCD risk of 12% in patients with advanced
HF but without syncope2. Several studies identiﬁed syncope to, a division of Reed Elsevier India, Pvt. Ltd. All rights reserved.
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cardiomyopathy (DCM) patients.3,4
However, the occurrence of syncope in patients with DCM is
not yet completely understood. The cause often remains
undiagnosed after standardized evaluation and the relation-
ship between syncope and death in HF patients remains
vaguely characterized. The mechanisms of syncope in DCM
patients are diverse, including cardiac diseases such as
ventricular and supraventricular arrhythmias, bradycardia,
conduction disorders, and valvular stenosis. Noncardiac
causes are neurally mediated5 and those attributed to
orthostatic hypotension (OH) or neurological pathology6,7.
Since syncope is associated with an increased mortality in
patients with DCM, identifying risk factors for the occurrence of
syncope in these patients is important. In the general popula-
tion, risk factors for syncope include advanced age8, the
presence of an underlying heart disease, autonomic dysfunc-
tion, drugs (vasodilators, diuretics, alcohol), and volume
depletion9. Whether patients with DCM have the same risk
factors or whether there are other risk factors for syncope in
these patients is less known. Therefore, the aim of this study
was to assess the prevalence of syncope, to describe the
underlying mechanisms and to identify risk factors for syncope
in patients with DCM.
2. Methods
All data were collected retrospectively from the patients'
medical records. The medical ﬁles of 897 patients with a
diagnosis of DCM, admitted for syncope from January 2008 to
December 2013 to the Cardiology Department of the Rehabili-
tation Hospital in Cluj-Napoca, Romania were reviewed.
Patients with syncope were identiﬁed and their clinical and
paraclinical proﬁles were compared to an equal number of
age- and sex-matched patients with DCM without syncope.
Patients from the control group were chosen in a chronological
order according to the admission date.
The studied parameters included DCM etiology, left
ventricular ejection fraction (LVEF), New York Heart Associa-
tion (NYHA) class severity, and the presence of associated
conditions: atrial ﬁbrillation (AF), type 2 diabetes mellitus (DM
II), hypertension, and dyslipidemia.
2.1. Patient workup for syncope
The protocol for the assessment of patients with syncope at
our hospital includes
- detailed history taking and a complete physical examina-
tion.
- blood pressure measurement in both arms, both in a supine
position and during standing, to identify patients with
orthostatic hypotension.
- a neurological exam performed by a certiﬁed neurologist, to
rule out neurological causes of transient loss of conscious-
ness.
- blood sample testing, including a complete blood count, blood
glucose level, blood urea nitrogen, serum creatinine, total
cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides,aspartate amino transferase (ASAT), alanine amino transfer-
ase (ALAT), uric acid, Quick time, INR.
- a standard 12 lead ECG carefully assessed for the presence of
brady- or tachy-arrhythmias, conduction disorders such as
AV block or bundle branch block, the presence of ischemic
changes, ventricular pre-excitation, QT prolongation or
shortening, and Brugada-like changes.
- a trans-thoracic echocardiography using an Esaote MyLab 50
echocardiograph, to identify anatomical modiﬁcations such
as atria or ventricular dilation, the presence of hypertrophy
or cardiac masses, to quantify the LV ejection fraction (LVEF),
to assess valve status, the presence of pericardial effusion,
signs of cardiac tamponade, aortic dissection, and pulmo-
nary embolism, to characterize the diastolic function, global
and regional kinetics, and to measure the pulmonary artery
pressure.
- a 24 h Holter ECG monitoring using a BTL CardioPoint H600
device, to assess the minimum, average and maximum heart
rates, as well as the presence of arrhythmias and conduction
disorders.
- a head-up tilt table test and carotid sinus massage,
performed in patients in which history taking suggests
elements in favor of a vaso-vagal syncope or carotid sinus
hypersensitivity.
- an electrophysiological study (EPS), in patients in which an
arrhythmia or a conduction disorder is suspected based on
noninvasive tests.
Based on these clinical and paraclinical data, the clinician's
judgment established the cause of syncope.
2.2. Deﬁnitions
Syncope was deﬁned as an episode of transient loss of
consciousness with incapacity to maintain postural tone,
with sudden onset, short duration and complete, and
spontaneous recovery.9
The deﬁnition of DCM was based on the existence of a
progressive heart muscle disease with cavity enlargement and
diminished performance of the left ventricle (LVEF < 55%), in
the absence of left ventricular hypertrophy, with or without
enlargement of the right ventricle. The upper limit of the
normal left ventricular diastolic diameter for males and
females was deﬁned as 59 mm and 53 mm, respectively 10.
The etiology of cardiomyopathy was differentiated into
primary (idiopathic) and secondary causes. DCM was consid-
ered idiopathic after secondary causes (such as ischemia,
severe valvular stenosis or regurgitation, a history of alcohol
abuse, a history of myocarditis, general systemic diseases,
muscular distrophies, neuromuscular disorders, use of
anthracyclines, irradiation and peripartum cardiomyopathy)
were excluded.
Atrial ﬁbrillation was diagnosed using the 12 lead ECG or
Holter ECG monitoring. Patients with all forms of atrial
ﬁbrillation: paroxysmal, persistent, and long-standing persis-
tent were included.
Diabetes mellitus was deﬁned as 2 values of fasting plasma
glucose >126 mg/dl, or an abnormal oral glucose tolerance
test, with a 2-h serum glucose after the ingestion of 75 g of
glucose of >198 mg/dl.11
Table 1 – General characteristics of patients with dilated
cardiomyopathy and syncope vs patients with dilative
cardiomyopathy and no syncope.
Patient characteristic Patients
with DCM
and
syncope
Patients
with
DCM but
no
syncope
p value
Number of patients 30 30 –
Sex (males) 27 27 –
Age (years) age  std
dev
62.53  10.74 62.6  10.06 0.84
Etiology of DCM
 Ischemia 12 (40%) 14 (46%)
 Alcohol 2 (7%) 2 (7%)
 Valve disease 1 (3.5%) 0 (0%)
 Mixed
(ischemia + alcohol)
7 (23%) 5 (17%)
 Mixed
(Alcohol + valve
disease)
2 (7%) 0 (0%) 0.55
 Idiopathic 6 (20%) 9 (30%)
Prevalence of syncope 3.3% 0% –
LVEF: average 35.3% 35.3% 1.0
≤35%, n (%) 18 (60%) 12 (40%) 0.19
 <15% 1 (3%) 0 (0%)
 15–25% 1 (3%) 4 (13%)
 25–35% 16 (53%) 8 (27%)
 35–45% 10 (33%) 17 (57%)
> 45% 2 (7%) 1 (3%)
NYHA class: n (%) 0.79
 NYHA class I, II 11 (37%) 12 (40%)
 NYHA class III, IV 19 (63%) 18 (60%)
Associated conditions:
n (%)
 Hypertension 12 (40%) 15 (50%) 0.36
 Diabetes mellitus 7 (23%) 6 (20%) 0.75
 Atrial ﬁbrillation 19 (63%) 16 (53%) 0.43
Dyslipidemia 26 (87%) 22 (73%) 0.33
DCM, dilated cardiomyopathy; LVEF, left ventricular ejection
fraction; NYHA, New York Heart Association; Std dev, standard
deviation.
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following: plasma total cholesterol >190 mg/dl, low-density
lipoprotein level cholesterol >115 mg/dl, triglycerides
>150 mg/dl, or a high-density lipoprotein level <40 mg/dl in
males and <46 mg/dl in females.12
Patients were considered hypertensive, when known with
arterial blood pressure levels of ≥140/90 mmHg13 or known
with prescribed antihypertensive therapy.
2.3. Statistical analysis
Data are presented as average  standard deviation for
continuous variable and frequencies (%) for categorical
variables.
The Mann–Whitney-U test was used for the comparison of
quantitative variables and the chi-squared test for the
comparison of qualitative variables. All statistical tests were
performed using SPSS (Statistical Package for the Social
Sciences). A p-value <0.05 was considered statistically signiﬁ-
cant.
3. Results
The general characteristics of patients included in the study
are presented in Table 1.
3.1. Prevalence, median age and sex distribution
Twenty-seven men and three women were identiﬁed with
DCM and syncope. The average age in the case group was
62.5 years and 62.6 years in the control group. The prevalence
of syncope in patients with DCM was 3.3%.
3.2. Dilated cardiomyopathy etiology
The etiologies of DCM in the two groups are presented in Fig. 1.
Patients were considered to have idiopathic DCM, if secondary
causes (ischemia, signiﬁcant valve disease, alcohol abuse)
were excluded. The encountered valve diseases were 1 case of
severe aortic regurgitation and 2 cases of severe mitral
regurgitation, all found in the case group. Ischemia was at
least partially responsible for 63% of cases in both the syncope
and control group. Alcohol abuse played a role in 37% of
patients with and 24% without syncope. Six (20%) cases in the
syncope group and 9 (30%) cases in the control group had no
identiﬁable cause.
3.2.1. Etiology of syncope in patients with DCM
A cardiac etiology was identiﬁed in 17 (56%) patients.
Ventricular arrhythmias (sustained monomorphic ventricular
tachycardia that either occurred spontaneously or was
induced during the EPS and polymorphic ventricular tachy-
cardia) were responsible for 10 (33%) cases and conduction
disorders (second and third degree AV block) for 7 (23%) cases
of syncope in patients with DCM. Seven percent of syncope
were caused by orthostatic hypotension and an equal number
were neurally mediated. In 9 (30%) cases no etiology was
identiﬁed (Fig. 2).3.3. LVEF distribution
In the DCM and syncope group, the LVEF varied between
15 and 51%. The average LVEF was 35.3%. The patient group
with DCM and no syncope had LVEF between 20 and 49%, with
an average LVEF of 35.3%. There was no statistically signiﬁcant
difference of LVEF distribution in the case and the control
group. The distribution of the LVEF in the 2 groups is presented
in Fig. 3.
3.4. NYHA class severity distribution
The distribution of patients according to the NYHA class is
presented in Fig. 4. The majority of patients in both groups
were in NYHA class II and III. No patient with NYHA class I was
found in either the case or the control group. Three (10%)
Fig. 1 – The distribution of dilated cardiomyopathy etiology in patients with syncope (left panel) and patients without syncope
(right panel).
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whereas no patient with syncope was identiﬁed with this
NYHA class.
There was no statistically signiﬁcant link between NYHA
class severity and the presence of syncope (p = 0.79).
3.5. Prevalence of associated conditions and risk factors
Arterial hypertension, type 2 diabetes mellitus, AF and
dyslipidemia were a relatively frequent ﬁnding in both groups
of patients, with hypertension and dyslipidemia having a
slightly higher prevalence in the syncope group: 40% vs 50%,
p = 0.36 and 87% vs 73%, p = 0.33 respectively. Atrial ﬁbrillation
was more frequently encountered in the syncope group (63%
vs 53%, p = 0.43), and DM II had a similar prevalence in both
groups (23% vs 20%, p = 0.75). However, there were no
signiﬁcant differences in the presence of these associated
conditions between the two groups.
3.6. Characteristics of patients according to the etiology of
syncope: cardiac vs noncardiac
The general characteristics of patients with cardiac vs
noncardiac syncope are presented in Table 2.Fig. 2 – Mechanisms of syncope in patients with dilated
cardiomyopathy.There were no statistically signiﬁcant differences between
patients with cardiac syncope and patients with noncardiac
syncope (neurally mediated, othostatic hypotension, and
unidentiﬁed cause) regarding age, sex, NYHA class, etiology
of DCM (idiopathic vs other), LVEF, the presence of atrial
ﬁbrillation and dyslipidemia. However, patients with a noncar-
diac cause of syncope were more likely to have hypertension
(61.53% vs 23.52%, p = 0.08) and diabetes mellitus (46.15% vs
5.88%, p = 0.03) compared to DCM patients with cardiac syncope.
4. Discussion
4.1. Prevalence of syncope in patients with DCM
In the present study, the prevalence of syncope is considerably
lower than the one in the ‘‘Sudden Cardiac Death in Heart
Failure Trial’’ (SCD-HeFT) study population (ischemic and
nonischemic cardiomyopathy patients with NYHA class II and
III and LVEF <35%)1. Olshansky et al. identiﬁed 19% of enrolled
subjects with at least one episode of syncope during a median
follow-up of 45.5 months. In 1993, Middlekauf et al.2 discov-
ered a syncope prevalence of 12% among subjects with
advanced HF.
4.2. Age and sex distribution of patients with syncope and
DCM
The average age in the study of Phang et al.14 was 59.5 years,
which is very similar to the median age from the present study.
However, the present male/female ratio differed greatly
from the one of the syncope group described by Phang et al.
(90%/10% vs 68%/32%). The results from the present study also
correlate with the ones found by Middlekauf et al.2, a study
population with 80% men. The same is true for Brembilla-
Perrot's et al. study15, where males made up 85% of each study
group respectively. One group comprised subjects with a
history of myocardial infarction and/or multiple coronary
stenosis on coronary angiography and LVEF <40%. The other
group included patients with idiopathic DCM and LVEF
between 10 and 40%. Mean age in the former group was
65 years and 62 years in the latter.
Fig. 3 – Left ventricular ejection fraction (LVEF) distribution in patients with dilated cardiomyopathy and syncope (left panel)
and without syncope (right panel).
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Ischemia was the most prevalent cause of DCM in both groups
of patients, representing almost two thirds of causes in each
group. Toxic cardiomyopathy was a relatively rare ﬁnding in
each of the two DCM groups. Middlekauf et al.2 demonstrated
48% of advanced HF cases to be due to coronary artery disease.
In his study, idiopathic DCM was responsible for 51%, a higher
percentage than the one from the present study, and valvular
heart disease for 5% of advanced HF cases, which is similar to
the one from the present study.
4.4. Assessment of LVEF and NYHA class
In the present study, there was no correlation between the
presence of syncope and the LVEF.
In their study, Middlekauf et al.2 compared the means LVEF
of HF patients with syncope to HF patients without syncope.
The syncope group contained 60 subjects and the control
group 431 patients. No statistically signiﬁcant correlation was
obtained between the presence of syncope and the LVEF.
Olshansky et al.1 compared HF patients with a LVEF < 25% to
those with a LVEF > 25% regarding the occurrence of syncope,Fig. 4 – Patient distribution according to the NYHA class.
Blue columns = patients with dilated cardiomyopathy and
syncope. Red columns = patients with dilated
cardiomyopathy and no syncope.ﬁnding no correlation between the occurrence of syncope and
the LVEF.
In the present study, almost two thirds with DCM and
syncope were found in NYHA class III, comprising patients
with a less advanced state of HF compared to the population
included in the study of Middlekauf et al.2, where most of the
patients with syncope were in NYHA class IV (58%).
We found no statistically signiﬁcant correlation between
the NYHA class severity and the prevalence of syncope in DCM
patients. In contrast to our ﬁnding is the study of Olshansky
et al.1, who compared the prevalence of syncope according to
the NYHA class (class II vs class III) and established a
statistically signiﬁcant correlation between the NYHA class
severity and the presence of syncope. One of the possible
explanations might be the differences in the population
characteristics (a larger population included in Olshansky's
study, with all patients having an EF ≤35%).
4.5. Associated conditions and risk factors
No correlation between syncope and the presence of hyper-
tension, AF, DM II and dyslipidemia was identiﬁed. We thinkTable 2 – General characteristics of patients with dilated
cardiomyopathy and cardiac syncope vs patients with
dilated cardiomyopathy and noncardiac syncope.
Patients
with
cardiac
syncope
Patients
with
noncardiac
syncope
p value
Age (years) 62.07  8.28 62.88  12.54 0.84
Sex (Males): n (%) 13 (100%) 14 (82.35%) 0.32
NYHA class II: n (%) 3 (23.07%) 8 (47.05% 0.33
NYHA class III: n (%) 10 (76.93%) 9 (52.95%) 0.33
DCM etiology:
idiopathic
3 (23/07%) 3 (17.63%) 0.71
Associated conditions: n (%)
 Hypertension 8 (61.53%) 4 (23.52%) 0.08
 Diabetes mellitus 6 (46.15%) 1 (5.88%) 0.03
 Atrial Fibrillation 5 (38.46%) 11 (64.70%) 0.28
 Dyslipidemia 11 (84.61%) 15 (88.23%) 0.77
DCM, dilated cardiomyopathy; NYHA, New York Heart Association.
Bold value = statistically signiﬁcant.
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number of patients included in the study was not enough to
reach statistical signiﬁcance, or (2) there may be no relation-
ship between these associated conditions and syncope in
patients with DCM. This is in concordance with the results of
the study by Olshansky et al.1, who compared the prevalence
of syncope in HF patients with and without AF and found no
statistically signiﬁcant link.
In contrast to our results, Middlekauf et al.2 compared the
prevalence of AF between patients with DCM and syncope and
patients with DCM and no syncope and identiﬁed a statisti-
cally signiﬁcant correlation between the presence of AF and
syncope. Sanchez et al.16 assessed the frequency of HTN, DM II
and dyslipidemia in patients with syncope and cardiomyopa-
thy who had a negative EPS. This group comprised 19 subjects.
HTN was present in 10 (53%), DM II in 6 (32%) and dyslipidemia
in 8 (42%) subjects who received ICD therapy. Our values are
congruent with these, except for dyslipidemia. The difference
may be explained by the fact that in our study, patients with
exclusive hypo-high-density-lipoproteinemia were consid-
ered to have dyslipidemia.
4.6. Etiology of syncope
Cardiac causes represent the most common etiology of
syncope in congestive HF and primary DCM patients, with
ventricular tachycardia being the most common cause 6. This
is in concordance with our study, in which ventricular
arrhythmias and conduction disturbances together made up
more than half of syncope cases in DCM patients. Other
cardiac causes encompass supraventricular arrhythmia, bra-
dycardia, conduction disturbance, and valvular stenosis.
Noncardiac causes are reﬂex-mediated syncope and those
attributed to orthostatic hypotension (OH) or neurological
pathology. Neurocardiogenic mechanisms also play a role in
DCM patients with syncope of unknown cause. However, OH
and reﬂex mediated syncope had a low prevalence in the
present study. OH was found responsible in 65 (14%) out of 458
syncope events affecting the post randomization group of the
SCD-HeFT1 and Middlekauf et al.2 established 15% of cases in
patients with congestive HF and syncope to result from OH.
The latter additionally established 48% of cases to be due to
cardiac causes, which concords with our results.
It is important to note that no etiology could be identiﬁed in
almost a third of the patients, which is in agreement with the
study of Middlekauf et al., in which 30% of patients with
advanced HF and syncope remained with no identiﬁed
etiology. These percentages are higher than the one found
in the SCD-HeFT trial, where only 19% of patients with syncope
had no identiﬁable cause.
4.7. Characteristics of patients according to the etiology of
syncope: cardiac vs noncardiac
There were no statistically signiﬁcant differences between
patients with cardiac syncope and patients with noncardiac
syncope (neurally-mediated, othostatic hypotension and
unidentiﬁed cause) regarding age, sex, NYHA class, etiology
of DCM (idiopathic vs other), LVEF, the presence of atrial
ﬁbrillation and dyslipidemia. However, patients with anoncardiac cause of syncope were more likely to have
hypertension and diabetes mellitus compared to DCM patients
with cardiac syncope, which is not surprising, since one of the
most common causes of orthostatic hypotension is autonomic
neuropathy due to diabetes mellitus. Also, it is known that
hypertensive patients are more likely to have syncope due to
orthostatic hypotension and neurally-mediated syncope,
since most anti-hypertensive drugs (ACE inhibitors, angioten-
sin receptor blockers, diuretics, beta blockers, calcium channel
blockers alpha central blockers) can cause orthostatic hypo-
tension or excessive reduction in blood pressure values.
4.7.1. Current clinical situation and future directions
Our study contributes to the rather small amount of existing
data in the ﬁeld. As in previous studies, we established that
the etiology of syncope in patients with DCM cannot be
established in a signiﬁcant number of cases. We did not ﬁnd
any signiﬁcant correlation between the analyzed character-
istics and the occurrence of syncope in DCM patients. As
previously stated, other studies demonstrated a statistically
signiﬁcant relation between certain associated conditions
(AF, NYHA class severity) and syncope. This implies the need
for a larger study on the topic in the future in order to further
understand not only the correlations of associated conditions
with syncope, but also the mechanisms causing it. This is
especially true since syncope is known to be a negative
prognostic factor in patients with HF and the understanding
of mechanisms and etiology is crucial in order to improve
treatment options.
4.8. Limitations
This study is a retrospective study and carries all the
disadvantages and bias possibilities of a retrospective study.
The small number of patients included in the study might
have inﬂuenced the results.
The diagnosis was evidence-based in most cases. However,
it was the clinician's judgment who established the presump-
tive cause of syncope. In a few number of cases, the diagnosis
was based mainly on the patient's clinical history and
arguments in favor of a speciﬁc condition. For example, in
patients with inducible VT during the EPS, the cause of
syncope was considered VT, even though this was not 100%
certain, since no patient had ECG monitoring at the time of
syncope.
5. Conclusions
Syncope in patients with DCM is a relatively rare ﬁnding.
Cardiac causes (arrhythmias and conduction disorders) are
responsible for the majority of the cases of syncope, even
though up to a third of cases remain with an unidentiﬁed
etiology. Risk factors for syncope in patients with DCM remain
to be determined.
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